ALK and neoplasm: After feeding crizotinib, the tumor volumes of EML4-ALK (V1) and TTC7A-ALK groups were significantly reduced, which indicated that NIH3T3 cells expressing EML4-ALK (V1) and TTC7A-ALK were highly sensitive to crizotinib treatment in vivo (Fig. 4D).